

Application No. 10/699,683
Amdt. dated September 26, 2005
Reply to Office Action of May 9, 2005

2

Amendments to the Specification:

Please replace the following paragraph on page 1 before the first line of specification:

"REFERENCE TO RELATED APPLICATIONS

This application is a division of copending United States Patent application No. 09/453,289 filed December 3, 1999 (now U.S. Patent No. 6,676,949), which itself claims priority pursuant to 35 USC 119(e) from US Provisional Patent Application No. 60/110,885 filed December 4, 1998 (now abandoned)."

Please replace the paragraph beginning at page 4, line 21, with the following amended paragraph:

"Copending United States Patent Application No. 08/893,381 filed July 11, 1996 (now U.S. Patent No. 6,235,290) (WO 98/02546), assigned to University of Manitoba and the disclosure of which is incorporated herein by reference, describes an immunogenic composition for *in vivo* administration to a host for the generation in the host of a protective immune response to a major outer membrane protein (MOMP) of a strain of *Chlamydia*, comprising a non-replicating vector comprising a nucleotide sequence encoding a MOMP or MOMP fragment that generates a MOMP specific immune response, and a promoter sequence operatively coupled to the nucleotide sequence for expression of the MOMP or MOMP fragment in the host; and a pharmaceutically-acceptable carrier therefor."

Application No. 10/699,683
Amdt. dated September 26, 2005
Reply to Office Action of May 9, 2005

3

Please replace the paragraph beginning at page 4, line 31, with the following amended paragraph:

"Copending United States Patent Application No. 08/713,236 filed September 16, 1996 (now U.S. Patent No. 6,464,969) (WO 98/10789), assigned to Connaught Laboratories Limited and the disclosure of which is incorporated herein by reference, describes an immunogenic composition, comprising the major outer membrane protein (MOMP) of a strain of *Chlamydia*, which may be *Chlamydia trachomatis*, and an immunostimulating complex (ISCOM)."

Please replace the paragraph beginning at page 9, line 4, with the following amended paragraph:

"A pMOMP expression vector was made as described in the aforementioned US Patent Application No. 08/893,381 (now U.S. Patent No. 6,235,290) (WO 98/02546). Briefly, the MOMP gene was amplified from *Chlamydia trachomatis* mouse pneumonitis (MoPn) strain genomic DNA by polymerase chain reaction (PCR) with a 5' primer (GGGGATCCGCCACCATGCTGCCTGTGGGGAATCCT) (SEQ ID NO:1) which includes a BamHI site, a ribosomal binding site, an initiation codon and the N-terminal sequence of the mature MOMP of MoPn and a 3' primer (GGGGCTCGAGCTATTAACGGAAGTGAAGC) (SEQ ID NO:2) which includes the C-terminal sequence of the MoPn MOMP, XhoI site and a stop codon. The DNA sequence of the MOMP leader peptide gene sequence was excluded. After digestion with BamHI and XhoI, the PCR product was cloned into the pcDNA3 eukaryotic II-selectable expression vector (Invitrogen, San Diego) with transcription under control of the human cytomegalovirus major intermediate early enhancer region (CMV promoter). The MOMP gene-encoding plasmid was transferred by electroporation into *E. coli*

Application No. 10/699,683
Amdt. dated September 26, 2005
Reply to Office Action of May 9, 2005

4

DH5 α F which was grown in LB broth containing 100 μ g/ml of ampicillin. The plasmids was extracted by Wizard™ Plus Maxiprep DNA purification system (Promega, Madison). The sequence of the recombinant MOMP gene was verified by PCR direct sequence analysis, as described (ref. 44). Purified plasmid DNA was dissolved in saline at a concentration of 1 mg/ml. The DNA concentration was determined by DU-62 spectrophotometer (Beckman, Fullerton, CA) at 260 nm and the size of the plasmid was compared with DNA standards in ethidium bromide-stained agarose gel."